- Home
- VTRS
VTRS
Viatris Inc.
as 12-18-2024 2:43pm EST
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
| Founded: | 1961 | Country: | United States |
| Employees: | N/A | City: | CANONSBURG |
| Market Cap: | 15.6B | IPO Year: | N/A |
| Target Price: | $13.67 | AVG Volume (30 days): | 7.1M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.93 - $13.62 | Next Earning Date: | 11-07-2024 |
| Revenue: | $15,048,500,000 | Revenue Growth: | -2.70% |
| Revenue Growth (this year): | -1.92% | Revenue Growth (next year): | -2.48% |
Stock Insider Trading Activity of Viatris Inc. (VTRS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Campbell Paul | VTRS | See Remarks | Nov 11 '24 | Sell | $12.88 | 26,925 | $346,686.30 | 126,901 |
Latest Viatris Inc. News
VTRS Breaking Stock News: Dive into VTRS Ticker-Specific Updates for Smart Investing
PR Newswire
8 hours ago
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology
MT Newswires
12 days ago
Piper Sandler Adjusts Price Target on Viatris to $14 From $13, Keeps Neutral Rating
MT Newswires
a month ago
Viatris Fined $1.9 Million Over Alleged Violation of Antitrust Restrictions
Reuters
a month ago
Viatris fined in Morocco over merger notification, sources say
Zacks
a month ago
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
Pharmaceutical Technology
a month ago
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
GuruFocus.com
a month ago
Viatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...
Investopedia
a month ago
S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate
Compare VTRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTRS Viatris Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.